SCHEMBL3516100

SCHEMBL3516100

CCOC(=O)CNC(=O)c1c(O)ccc2nc(Br)cnc12

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.43
HSD17B10 Q99714 2/20 0.42
EGLN3 Q9H6Z9 2/20 0.41
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 4/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 1/20 0.37
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TP53 P04637 1/20 0.36
GLA P06280 1/20 0.36
POLB P06746 1/20 0.36
PPID Q08752 1/20 0.35
VEGFA P15692 1/20 0.35
FLT1 P17948 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3516187 0.89 HSD17B10 (0.46) HPGDHSD17B10EGLN3NPC1RAB9A
SCHEMBL3522309 0.83 EGLN3 (0.57) EGLN3EGLN1
SCHEMBL3518478 0.83 EGLN3 (0.50) HPGDHSD17B10EGLN3NPC1RAB9A
SCHEMBL3755568 0.82 HPGD (0.49) HPGDHSD17B10EGLN3NPC1RAB9A
SCHEMBL3759035 0.82 CASP1 (0.40) HPGDHSD17B10EGLN3NPC1RAB9A
SCHEMBL3521384 0.82 CASP1 (0.49) HPGDHSD17B10EGLN3NPC1RAB9A
SCHEMBL3761637 0.82 HPGD (0.46) HPGDHSD17B10EGLN3NPC1RAB9A
SCHEMBL3760728 0.81 HPGD (0.41) HPGDHSD17B10EGLN3NPC1RAB9A
SCHEMBL3766318 0.81 MAPT (0.39) HPGDHSD17B10EGLN3NPC1RAB9A
SCHEMBL3757575 0.81 CYP3A4 (0.39) HPGDHSD17B10EGLN3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 HPGD 51/4885HSD17B10 613/4885EGLN3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.